Clinical Compound Banklol外围平台

LOL下注网站


lol外围平台

LOL下注网站

Every scientist involved in medical research knows 关于 the challenges posed by limited resources and expertise, and the hard choices one must make in terms of prioritising research activities.

LOL下注网站

  • Explore our Clinical Table of Compounds and examine the key properties of any compound/mechanism of interest
  • Learn the process, criteria, and rough timelines for proposal submission through to full project plan development and final approval
  • Submit a short 2-3 page ‘Concept Proposal’.

Additional marketed, biologic and late-stage clinical development compounds are offered via the AstraZeneca Externally Sponsored Scientific Research portal.


lol外围平台

lol外围平台

lol外围平台

lol外围平台




LOL下注网站



LOL下注网站

Addressing Intellectual Property (IP) is key to promoting open innovation. It’s essential that we build mutual trust and reward innovation – this means if one party generates IP, they get rewarded and recognized for it. If we create new IP as a result of our collaboration, then we work out how to share it on a case-by-case basis in a way that works for both parties.

Dr. Menelas Pangalos EVP, R&D BioPharmaceuticals, AstraZeneca



LOL下注网站

Filter By

Display
Compound Mechanism of action Originating therapeutic area Proposal type CNS Penetrant Target Class Original Indication Route
AZD0328 Mechanism of action Nicotinic acetylcholine receptor alpha 7 (α7 nAChR) agonist Originating therapeutic area CNS Proposal type Clinical & Preclinical CNS Penetrant Yes Target Class Ligand-gated ion channel Original Indication Cognitive impairment Route Oral
AZD1236 Mechanism of action Matrix metalloproteinase 9 & 12 (MMP9,12) inhibitor Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target Class Enzyme Original Indication COPD Route Oral
AZD1656 Mechanism of action Glucokinase (GK; hexokinase 4) activator Originating therapeutic area Metabolic Disease Proposal type Clinical & Preclinical CNS Penetrant Low Target Class Enzyme Original Indication Diabetes Route Oral
AZD1775 Mechanism of action WEE1 G2 checkpoint kinase inhibitor  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Unknown Target Class Kinase Original Indication Advanced Solid Tumours Route Oral
AZD1981 Mechanism of action Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist [prostaglandin D2 (DP2) receptor antagonist] Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target Class GPCR Original Indication Asthma, COPD Route Oral
AZD2014 Mechanism of action Mammalian target of rapamycin (mTOR) serine/threonine kinase (dual TORC1 and TORC2) inhibitor  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Unknown Target Class Kinase Original Indication Solid Tumours Route Oral
AZD5069 Mechanism of action Chemokine (C-X-C motif) receptor 2 (CXCR2) antagonist Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Unknown Target Class GPCR Original Indication Asthma Route Oral
AZD5213 Mechanism of action Histamine receptor 3 (H3) antagonist (inverse agonist) Originating therapeutic area CNS Proposal type Clinical & Preclinical CNS Penetrant Yes Target Class GPCR Original Indication Cognition, Daytime Sleepiness, Tourette's Route Oral
AZD5904 Mechanism of action Myeloperoxidase (MPO) inhibitor Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target Class Enzyme Original Indication COPD, MS Route Oral
AZD9150 Mechanism of action Signal transducer and activator of transcription 3 (STAT3) antisense  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Low Target Class Antisense Original Indication Hepatocellular Carcinoma Route IV
Lesogaberan (AZD3355) Mechanism of action Gamma-aminobutyric acid receptor B (GABAB) agonist   Originating therapeutic area GI Proposal type Clinical & Preclinical CNS Penetrant Low Target Class GPCR Original Indication GERD Route Oral

LOL下注网站

AstraZeneca collaborates with various government funding bodies and academic institutions to provide funding opportunities for studies that use our compounds.

lol外围平台

National Health Innovation Centre (Singapore)

Taiwan’s National Research Program for Biopharmaceuticals (NRPB) (Taiwan)

University of Queensland (Australia)



LOL下注网站


How do I know that the information I submit to AstraZeneca will remain confidential?lol外围平台

AstraZeneca is committed to the same ethical policy that is practiced during grant and manuscript peer-reviews. We will not use or disclose information you submit, unless you approve in writing, or the information becomes public, is separately received or independently developed.

What are the typical agreement terms?lol外围平台

The AstraZeneca Open Innovation program seeks to utilize terms that facilitate participation, open collaborative brainstorming, problem solving and are consistent with well-established and tested academic-industry agreement structures (e.g., Lambert/miCRA templates in U.K. and NIH/NCATS CRA in U.S.), for example:

  • Pre-existing IP remains with the original owner
  • New IP follows ownership framework taking into account the contribution of each party and where possible using the well-established academic-industry templates
  • Publications are encouraged after allowing AstraZeneca to comment, patent(s) to be filed (if applicable), AstraZeneca confidential information protected
  • If the collaboration generates positive findings, AstraZeneca has option to negotiate a license to advance further towards patient benefit and commercialization
  • For compounds ‘live’ in development, AstraZeneca minimally receives non-exclusive, royalty-free, fully paid license, with the right to sublicense without limitation, for all purposes for project IP.

In general, Collaborative Research Agreement (CRA) and/or Clinical Trial Agreement (CTA) are/is negotiated for an agreed upon Full Project Proposal/Plan.

1.     Ownership of project IP and rewards (e.g., royalties) if positive data found are based on multiple factors including regional/country standards, IP policies and the current development stage/status of the compound.

2.     AstraZeneca has at least an option to negotiate a license for project IP.